Travere Therapeutics, Inc. (TVTX) on GreekSoup https://greeksoup.ai/stocks/us/tvtx/ Every dated entry in the public record on Travere Therapeutics, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Wed, 28 Oct 2026 00:00:00 +0000 Travere Therapeutics, Inc.: Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 128,065 shares (under a trading plan set in advance) at $52.97 on 15 October 2026, $6.8 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-10-19:548ab40a7cMon, 19 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 37,270 shares (under a trading plan set in advance) at $54.20 on 15 October 2026, $2.0 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-10-19:3753ecd30cMon, 19 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 78,400 shares (under a trading plan set in advance) at $55.02 on 15 October 2026, $4.3 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-10-19:a71407d251Mon, 19 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, ERIC DUBE plans to sell 243,735 shares worth $13.0 million around 15 October 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-10-15:cae5ef6972Thu, 15 Oct 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: short interest 10,913,583 shares at the 15 October 2026 settlement, 5.24 days to coverhttps://greeksoup.ai/stocks/us/tvtx/short-interest/us:TVTX:short-interest:2026-10-15:8da9bdbcd5Thu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: short interest 12,655,839 shares at the 30 September 2026 settlement, 7.23 days to coverhttps://greeksoup.ai/stocks/us/tvtx/short-interest/us:TVTX:short-interest:2026-09-30:d8083cb725Wed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc. filed 8-K: officer or director changehttps://greeksoup.ai/stocks/us/tvtx/filings/us:TVTX:filing:2026-09-21:45cb130239Mon, 21 Sep 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, PETER HEERMA plans to sell 8,282 shares worth $525,741 around 17 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-17:807fcff2e2Thu, 17 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, ERIC DUBE plans to sell 108,493 shares worth $6.9 million around 17 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-17:61bdf155d4Thu, 17 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Heerma Peter (EVP, CHIEF COMMERCIAL OFFICER) sold 8,282 shares (under a trading plan set in advance) at $65.07 on 17 September 2026, $538,917https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:bacf32be56Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 101,691 shares (under a trading plan set in advance) at $64.59 on 17 September 2026, $6.6 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:d15a12eb26Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 6,802 shares (under a trading plan set in advance) at $64.95 on 17 September 2026, $441,795https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:d6fe04fedcThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Rote William E. (Chief Research Officer) sold 65,104 shares (under a trading plan set in advance) at $63.12 on 16 September 2026, $4.1 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:289ff3911cThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Rote William E. (Chief Research Officer) sold 47,746 shares (under a trading plan set in advance) at $63.61 on 16 September 2026, $3.0 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:3f94e17657Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Heerma Peter (EVP, CHIEF COMMERCIAL OFFICER) sold 93,604 shares (under a trading plan set in advance) at $63.25 on 16 September 2026, $5.9 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:27fdec0972Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Heerma Peter (EVP, CHIEF COMMERCIAL OFFICER) sold 79,113 shares (under a trading plan set in advance) at $63.65 on 16 September 2026, $5.0 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:d8153c7243Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 99,716 shares (under a trading plan set in advance) at $63.26 on 16 September 2026, $6.3 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:b833f4d59aThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 96,125 shares (under a trading plan set in advance) at $63.64 on 16 September 2026, $6.1 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:6a55e85996Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Rote William E. (Chief Research Officer) sold 63,907 shares (under a trading plan set in advance) at $61.99 on 15 September 2026, $4.0 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:464cd4e7ebThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Rote William E. (Chief Research Officer) sold 29,021 shares (under a trading plan set in advance) at $62.66 on 15 September 2026, $1.8 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:50caf6dc8aThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Rote William E. (Chief Research Officer) sold 3,000 shares (under a trading plan set in advance) at $63.65 on 15 September 2026, $190,952https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:a73dd011f9Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Rote William E. (Chief Research Officer) sold 270 shares (under a trading plan set in advance) at $65.31 on 15 September 2026, $17,634https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:0f9959c289Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Heerma Peter (EVP, CHIEF COMMERCIAL OFFICER) sold 71,938 shares (under a trading plan set in advance) at $62.05 on 15 September 2026, $4.5 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:7baa94b48dThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Heerma Peter (EVP, CHIEF COMMERCIAL OFFICER) sold 27,421 shares (under a trading plan set in advance) at $62.59 on 15 September 2026, $1.7 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:ba46f9cd3dThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Heerma Peter (EVP, CHIEF COMMERCIAL OFFICER) sold 1,400 shares (under a trading plan set in advance) at $63.65 on 15 September 2026, $89,113https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:1e88671543Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Heerma Peter (EVP, CHIEF COMMERCIAL OFFICER) sold 1,431 shares (under a trading plan set in advance) at $65.31 on 15 September 2026, $93,458https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:e6e80827c8Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Inrig Jula (EVP, Head of R&D & CMO) sold 25,390 shares (under a trading plan set in advance) at $62.02 on 15 September 2026, $1.6 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:4fb079d369Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Inrig Jula (EVP, Head of R&D & CMO) sold 17,284 shares (under a trading plan set in advance) at $62.62 on 15 September 2026, $1.1 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:34425a0c64Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Inrig Jula (EVP, Head of R&D & CMO) sold 1,600 shares (under a trading plan set in advance) at $63.69 on 15 September 2026, $101,896https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:2ff08b6cc5Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Inrig Jula (EVP, Head of R&D & CMO) sold 400 shares (under a trading plan set in advance) at $65.31 on 15 September 2026, $26,124https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:b1f7904b93Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Reed Elizabeth E (Chief Legal Officer and GC) sold 21,926 shares (under a trading plan set in advance) at $62.03 on 15 September 2026, $1.4 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:a53f1c71b5Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Reed Elizabeth E (Chief Legal Officer and GC) sold 13,874 shares (under a trading plan set in advance) at $62.63 on 15 September 2026, $868,965https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:7d72228199Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Reed Elizabeth E (Chief Legal Officer and GC) sold 1,400 shares (under a trading plan set in advance) at $63.69 on 15 September 2026, $89,166https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:f3600a9b6bThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Reed Elizabeth E (Chief Legal Officer and GC) sold 300 shares (under a trading plan set in advance) at $65.31 on 15 September 2026, $19,593https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:f15ea87a32Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 63,498 shares (under a trading plan set in advance) at $61.99 on 15 September 2026, $3.9 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:9f4bf2e5ceThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 28,796 shares (under a trading plan set in advance) at $62.66 on 15 September 2026, $1.8 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:1b1fec8effThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 3,102 shares (under a trading plan set in advance) at $63.64 on 15 September 2026, $197,422https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:d1e0d348d2Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Dube Eric M (CHIEF EXECUTIVE OFFICER) sold 270 shares (under a trading plan set in advance) at $65.31 on 15 September 2026, $17,634https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:c91a0852a9Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Cline Christopher R. (CHIEF FINANCIAL OFFICER) sold 27,473 shares (under a trading plan set in advance) at $62.00 on 15 September 2026, $1.7 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:51e654e0f7Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Cline Christopher R. (CHIEF FINANCIAL OFFICER) sold 20,735 shares (under a trading plan set in advance) at $62.61 on 15 September 2026, $1.3 millionhttps://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:f6cfe033baThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Cline Christopher R. (CHIEF FINANCIAL OFFICER) sold 1,900 shares (under a trading plan set in advance) at $63.69 on 15 September 2026, $121,004https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:1db300079eThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Cline Christopher R. (CHIEF FINANCIAL OFFICER) sold 400 shares (under a trading plan set in advance) at $65.31 on 15 September 2026, $26,124https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:f680ccdeecThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) sold 4,275 shares (under a trading plan set in advance) at $62.13 on 15 September 2026, $265,627https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:ec3b6cbba5Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) sold 800 shares (under a trading plan set in advance) at $62.85 on 15 September 2026, $50,278https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:ad9ad9e4daThu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Calvin Sandra (SVP, CHIEF ACCOUNTING OFFICER) sold 300 shares (under a trading plan set in advance) at $63.66 on 15 September 2026, $19,099https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-17:fa7fed0b59Thu, 17 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, WILLIAM ROTE plans to sell 112,850 shares worth $7.1 million around 16 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-16:8a8176793cWed, 16 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, PETER HEERMA plans to sell 172,717 shares worth $10.8 million around 16 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-16:4c9886cb68Wed, 16 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, ERIC DUBE plans to sell 195,841 shares worth $12.2 million around 16 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-16:d2a9697613Wed, 16 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, SANDRA CALVIN plans to sell 5,375 shares worth $353,621 around 15 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-15:141201dad3Tue, 15 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, ELIZABETH REED plans to sell 39,576 shares worth $2.6 million around 15 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-15:eb07e965ecTue, 15 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, JULA INRIG plans to sell 44,674 shares worth $2.9 million around 15 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-15:fee8dc94a9Tue, 15 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, CHRISTOPHER CLINE plans to sell 50,508 shares worth $3.3 million around 15 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-15:65422ee9cfTue, 15 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, ERIC DUBE plans to sell 95,666 shares worth $6.3 million around 15 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-15:666fcc891cTue, 15 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, WILLIAM ROTE plans to sell 96,198 shares worth $6.3 million around 15 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-15:ec1f51cf41Tue, 15 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, PETER HEERMA plans to sell 102,190 shares worth $6.7 million around 15 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-15:4757041a1cTue, 15 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: short interest 12,955,933 shares at the 15 September 2026 settlement, 10.38 days to coverhttps://greeksoup.ai/stocks/us/tvtx/short-interest/us:TVTX:short-interest:2026-09-15:96bea406a3Tue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Meckler Jeffrey A (Director) sold 1,700 shares (under a trading plan set in advance) at $65.39 on 10 September 2026, $111,166https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-11:dac336e904Fri, 11 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Meckler Jeffrey A (Director) sold 1,200 shares (under a trading plan set in advance) at $66.15 on 10 September 2026, $79,380https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-11:387a2e856dFri, 11 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Meckler Jeffrey A (Director) sold 14,000 shares (under a trading plan set in advance) at $67.46 on 10 September 2026, $944,488https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-11:e56b4ae710Fri, 11 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Meckler Jeffrey A (Director) sold 3,100 shares (under a trading plan set in advance) at $68.09 on 10 September 2026, $211,073https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-11:4d0dafb566Fri, 11 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, JEFFREY MECKLER plans to sell 20,000 shares worth $1.3 million around 10 September 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-09-10:065ca4c3d5Thu, 10 Sep 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Cline Christopher R. (CHIEF FINANCIAL OFFICER) sold 642 shares at $66.37 on 2 September 2026, $42,610https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-09-03:25406038e2Thu, 03 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: short interest 12,004,820 shares at the 31 August 2026 settlement, 9.56 days to coverhttps://greeksoup.ai/stocks/us/tvtx/short-interest/us:TVTX:short-interest:2026-08-31:593130352dMon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Lyons Gary A (Director) sold 4,100 shares (under a trading plan set in advance) at $63.27 on 18 August 2026, $259,390https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-08-19:13f899aa9dWed, 19 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Lyons Gary A (Director) sold 900 shares (under a trading plan set in advance) at $63.86 on 18 August 2026, $57,470https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-08-19:3eb484c3abWed, 19 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Lyons Gary A (Director) sold 1,900 shares (under a trading plan set in advance) at $62.53 on 17 August 2026, $118,805https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-08-19:d7bfdcbadeWed, 19 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Lyons Gary A (Director) sold 2,600 shares (under a trading plan set in advance) at $63.50 on 17 August 2026, $165,100https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-08-19:fc30ce773cWed, 19 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Lyons Gary A (Director) sold 500 shares (under a trading plan set in advance) at $64.16 on 17 August 2026, $32,081https://greeksoup.ai/stocks/us/tvtx/insiders/us:TVTX:insider:2026-08-19:662eab2fb8Wed, 19 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, GARY LYONS plans to sell 5,000 shares worth $317,650 around 18 August 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-08-18:76dd37c48bTue, 18 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Form 144, GARY A LYONS plans to sell 5,000 shares worth $310,700 around 17 August 2026https://greeksoup.ai/stocks/us/tvtx/planned-sales/us:TVTX:planned-sale:2026-08-17:f9d116ccd7Mon, 17 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Schedule 13G/A filed by Armistice Capital, LLC, 1.7% of the classhttps://greeksoup.ai/stocks/us/tvtx/holders/us:TVTX:schedule-13:2026-08-14:14c8a77029Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: short interest 11,943,638 shares at the 14 August 2026 settlement, 5.70 days to coverhttps://greeksoup.ai/stocks/us/tvtx/short-interest/us:TVTX:short-interest:2026-08-14:16f8514d83Fri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Schedule 13G filed by BANK OF AMERICA CORP /DE/, 5.8% of the classhttps://greeksoup.ai/stocks/us/tvtx/holders/us:TVTX:schedule-13:2026-08-12:fd7bcb0c65Wed, 12 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Schedule 13G filed by STATE STREET CORPORATION, 4.6% of the classhttps://greeksoup.ai/stocks/us/tvtx/holders/us:TVTX:schedule-13:2026-08-07:a11d63d523Fri, 07 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: Schedule 13G/A filed by FMR LLC, 7.7% of the classhttps://greeksoup.ai/stocks/us/tvtx/holders/us:TVTX:schedule-13:2026-08-06:a12b90891eThu, 06 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc. Q2 FY2026 results: revenue $170 million, net income -$35 millionhttps://greeksoup.ai/stocks/us/tvtx/results/fy2026-q2/us:TVTX:result:2026-08-04:504ec3608cTue, 04 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/tvtx/filings/us:TVTX:filing:2026-08-04:fd2e3f1abdTue, 04 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/tvtx/filings/us:TVTX:filing:2026-08-04:35dd531fe2Tue, 04 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Travere Therapeutics, Inc.: short interest 11,676,586 shares at the 31 July 2026 settlement, 9.41 days to coverhttps://greeksoup.ai/stocks/us/tvtx/short-interest/us:TVTX:short-interest:2026-07-31:46012838e3Fri, 31 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]>